Julie Bonner, MD
Psychiatry · Palo Alto
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Has dropped Medicare — you would pay privately
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bonner’s office at (650) 723-8335 to ask if they take your plan before you enroll.
California Medical Board record
Licence A80278 · Current
Licensed to practise in California · since 2002 · expires 2028-01-31 · Rosalind Franklin University, the Chicago Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$38,686
Pharmacies billed $38,686 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 144) in 2024. At or below the middle of the specialty; the typical psychiatry & neurology clinician is at 0%.
135 generic and fewer than 11 brand-name prescriptions · $38,686 in drug cost · 55 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clozapine | 11 | $1,079 | $98 |
| Quetiapine | 25 | $70 | $3 |
| Lamotrigine | 17 | $55 | $3 |
Year by year
| 2024 | 144 | None | 0% (0) | None | $38,686 |
| 2023 | 138 | None | 0% (0) | 12% | $65,268 |
| 2022 | 168 | None | 0% (0) | 13% | $92,539 |
| 2021 | 159 | None | 0% (0) | 14% | $68,273 |
| 2020 | 116 | None | 0% (0) | 18% | $64,680 |
| 2019 | 159 | None | 0% (0) | 26% | $73,998 |
| 2018 | 362 | 12 | 0% (0) | 23% | $53,081 |
| 2017 | 317 | None | None | 8% | $21,640 |
| 2016 | 283 | 14 | 0% (0) | 20% | $37,868 |
| 2015 | 162 | None | 0% (0) | 27% | $26,118 |
| 2014 | 145 | None | 0% (0) | 25% | $17,750 |
| 2013 | 108 | 12 | 0% (0) | 24% | $12,315 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Chlorpromazine | 11 | $6,621 | $602 |
| Quetiapine | 30 | $546 | $18 |
| Lamotrigine | 15 | $154 | $10 |
2022: 8 drugs
| Vraylar | 11 | $23,374 | $2,125 |
| Chlorpromazine | 13 | $7,476 | $575 |
| Quetiapine | 27 | $3,000 | $111 |
| Olanzapine | 12 | $743 | $62 |
| Trazodone | 12 | $355 | $30 |
| Clonazepam | 13 | $340 | $26 |
| Sertraline | 13 | $295 | $23 |
| Lamotrigine | 16 | $200 | $12 |
2021: 6 drugs
| Vraylar | 12 | $32,134 | $2,678 |
| Quetiapine | 26 | $1,385 | $53 |
| Trazodone | 13 | $482 | $37 |
| Clozapine | 16 | $382 | $24 |
| Clonazepam | 20 | $225 | $11 |
| Lamotrigine | 16 | $138 | $9 |
2020: 6 drugs
| Vraylar | 11 | $27,879 | $2,534 |
| Donepezil | 12 | $763 | $64 |
| Quetiapine | 18 | $645 | $36 |
| Clozapine | 18 | $284 | $16 |
| Trazodone | 14 | $195 | $14 |
| Clonazepam | 15 | $114 | $8 |
2019: 8 drugs
| Vraylar | 12 | $29,160 | $2,430 |
| Donepezil | 12 | $763 | $64 |
| Clozapine | 22 | $574 | $26 |
| Quetiapine | 17 | $412 | $24 |
| Trazodone | 13 | $206 | $16 |
| Lamotrigine | 16 | $168 | $10 |
| Levothyroxine | 12 | $136 | $11 |
| Clonazepam | 17 | $63 | $4 |
2018: 14 drugs
| Vraylar | 17 | $24,134 | $1,420 |
| Clozapine | 81 | $1,689 | $21 |
| Modafinil | 13 | $1,509 | $116 |
| Propranolol Hcl Er | 18 | $821 | $46 |
| Quetiapine | 25 | $646 | $26 |
| Desvenlafaxine Succinate Er | 12 | $537 | $45 |
| Lamotrigine | 34 | $453 | $13 |
| Lithium Carbonate Er | 13 | $354 | $27 |
| Bupropion Xl | 11 | $258 | $23 |
| Diazepam | 11 | $211 | $19 |
| Levothyroxine | 13 | $156 | $12 |
| Lithium Carbonate | 11 | $118 | $11 |
| Clonazepam | 13 | $47 | $4 |
| Metformin | 11 | $36 | $3 |
2017: 10 drugs
| Armodafinil | 11 | $3,803 | $346 |
| Modafinil | 11 | $870 | $79 |
| Quetiapine | 43 | $579 | $13 |
| Lithium Carbonate Er | 22 | $405 | $18 |
| Lamotrigine | 42 | $371 | $9 |
| Risperidone | 30 | $360 | $12 |
| Clonazepam | 11 | $211 | $19 |
| Diazepam | 17 | $204 | $12 |
| Propranolol | 19 | $174 | $9 |
| Levothyroxine | 11 | $98 | $9 |
2016: 10 drugs
| Pristiq | 25 | $7,603 | $304 |
| Paliperidone Er | 11 | $7,041 | $640 |
| Pramipexole Dihydrochloride | 25 | $850 | $34 |
| Lamotrigine | 40 | $438 | $11 |
| Quetiapine | 38 | $361 | $9 |
| Clonazepam | 16 | $341 | $21 |
| Levothyroxine | 14 | $233 | $17 |
| Lithium Carbonate Er | 12 | $139 | $12 |
| Fluoxetine | 15 | $134 | $9 |
| Escitalopram | 11 | $56 | $5 |
2015: 6 drugs
| Saphris | 12 | $10,285 | $857 |
| Pristiq Er | 15 | $4,898 | $327 |
| Quetiapine | 23 | $304 | $13 |
| Lamotrigine | 29 | $191 | $7 |
| Fluoxetine | 17 | $134 | $8 |
| Clonazepam | 12 | $66 | $6 |
2014: 6 drugs
| Saphris | 12 | $9,127 | $761 |
| Pristiq Er | 13 | $2,947 | $227 |
| Quetiapine | 18 | $1,369 | $76 |
| Lamotrigine | 39 | $360 | $9 |
| Levothyroxine | 14 | $191 | $14 |
| Clonazepam | 12 | $138 | $12 |
2013: 5 drugs
| Saphris | 12 | $8,370 | $697 |
| Pristiq Er | 12 | $2,484 | $207 |
| Lamotrigine | 33 | $512 | $16 |
| Quetiapine | 15 | $236 | $16 |
| Levothyroxine | 12 | $100 | $8 |
Money from drug and device companies
$37,986 in 2025
| 2025 | 3 | 49 | $33,353 | $37,986 |
| 2024 | 4 | 72 | $42,032 | $53,231 |
| 2023 | 3 | 57 | $36,390 | $40,446 |
| 2022 | 3 | 27 | $15,440 | $17,365 |
| 2021 | 3 | 42 | $30,700 | $33,865 |
| 2020 | 4 | 35 | $20,970 | $22,447 |
| 2019 | 6 | 87 | $38,665 | $46,391 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Vraylar | $16,824 | 26 payments
|
| Axsome Therapeutics | Auvelity | $12,733 | 17 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $8,428 | 6 payments
|
See all 49 published payments
| Axsome Therapeutics | Meals · 2025-12-19 | Auvelity | $28 |
| Abbvie | Meals · 2025-11-24 | Vraylar | $33 |
| Teva Pharmaceuticals USA | Meals · 2025-11-19 | Austedo Xr | $110 |
| Teva Pharmaceuticals USA | Travel · 2025-11-19 | Austedo Xr | $815 |
| Teva Pharmaceuticals USA | Paid to speak or teach · 2025-11-19 | Austedo Xr | $3,894 |
| Axsome Therapeutics | Education · 2025-11-14 | Auvelity | $44 |
| Teva Pharmaceuticals USA | Paid to speak or teach · 2025-11-14 | Austedo Xr | $1,198 |
| Abbvie | Meals · 2025-11-07 | Vraylar | $5 |
| Abbvie | Paid to speak or teach · 2025-11-06 | Vraylar | $2,750 |
| Axsome Therapeutics | Meals · 2025-10-30 | Auvelity | $30 |
| Axsome Therapeutics | Honoraria · 2025-10-29 | Auvelity | $1,650 |
| Axsome Therapeutics | Travel · 2025-10-29 | Auvelity | $769 |
| Abbvie | Meals · 2025-10-22 | Vraylar | $18 |
| Axsome Therapeutics | Meals · 2025-10-22 | Auvelity | $30 |
| Axsome Therapeutics | Honoraria · 2025-10-21 | Auvelity | $1,650 |
| Axsome Therapeutics | Travel · 2025-10-21 | Auvelity | $569 |
| Abbvie | Meals · 2025-10-01 | Vraylar | $17 |
| Abbvie | Paid to speak or teach · 2025-09-26 | Vraylar | $2,750 |
| Abbvie | Meals · 2025-09-26 | Vraylar | $124 |
| Abbvie | Meals · 2025-09-05 | Vraylar | $7 |
| Teva Pharmaceuticals USA | Consulting · 2025-08-25 | Austedo Xr | $560 |
| Axsome Therapeutics | Meals · 2025-07-25 | Auvelity | $22 |
| Axsome Therapeutics | Honoraria · 2025-07-24 | Auvelity | $1,650 |
| Abbvie | Meals · 2025-07-22 | Vraylar | $60 |
| Axsome Therapeutics | Meals · 2025-07-16 | Auvelity | $150 |
| Abbvie | Meals · 2025-07-11 | Vraylar | $12 |
| Abbvie | Meals · 2025-06-20 | Vraylar | $8 |
| Abbvie | Meals · 2025-06-07 | Vraylar | $22 |
| Axsome Therapeutics | Meals · 2025-05-29 | Auvelity | $38 |
| Abbvie | Meals · 2025-05-09 | Vraylar | $8 |
| Axsome Therapeutics | Meals · 2025-05-08 | Auvelity | $15 |
| Axsome Therapeutics | Meals · 2025-05-08 | Auvelity | $9 |
| Axsome Therapeutics | Honoraria · 2025-05-07 | Auvelity | $1,650 |
| Teva Pharmaceuticals USA | Paid to speak or teach · 2025-04-14 | Austedo Xr | $1,851 |
| Axsome Therapeutics | Honoraria · 2025-04-08 | Auvelity | $4,400 |
| Abbvie | Paid to speak or teach · 2025-04-07 | Vraylar | $2,750 |
| Abbvie | Meals · 2025-03-19 | Vraylar | $19 |
| Abbvie | Meals · 2025-03-14 | Vraylar | $7 |
| Abbvie | Paid to speak or teach · 2025-03-04 | Vraylar | $3,850 |
| Abbvie | Meals · 2025-03-03 | Vraylar | $22 |
| Abbvie | Paid to speak or teach · 2025-02-27 | Vraylar | $2,750 |
| Abbvie | Meals · 2025-02-21 | Vraylar | $11 |
| Abbvie | Meals · 2025-02-20 | Vraylar | $31 |
| Abbvie | Travel · 2025-02-20 | Vraylar | $942 |
| Axsome Therapeutics | Meals · 2025-02-12 | Auvelity | $29 |
| Abbvie | Meals · 2025-02-05 | Vraylar | $20 |
| Abbvie | Travel · 2025-02-05 | Vraylar | $571 |
| Abbvie | Meals · 2025-01-28 | Vraylar | $19 |
| Abbvie | Meals · 2025-01-24 | Vraylar | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $53,231
| Teva Pharmaceuticals USA | Austedo Xr | $33,664 | 44 payments
|
| Abbvie | Vraylar | $10,043 | 16 payments
|
| Axsome Therapeutics | Auvelity | $9,371 | 10 payments
|
| Vanda Pharmaceuticals | Fanapt | $153 | 2 payments
|
2023: $40,446
| AbbVie | Vraylar | $20,771 | 34 payments
|
| Teva Pharmaceuticals USA | Austedo | $19,650 | 22 payments
|
| Iti | Caplyta | $25 | 1 payment
|
2022: $17,365
| Abbvie | Vraylar | $9,519 | 15 payments
|
| Teva Pharmaceuticals USA | Austedo | $7,751 | 8 payments
|
| Sunovion Pharmaceuticals | Latuda | $95 | 4 payments
|
2021: $33,865
| AbbVie | Vraylar | $26,036 | 33 payments
|
| Teva Pharmaceuticals USA | Austedo | $7,795 | 7 payments
|
| Sunovion Pharmaceuticals | Latuda | $33 | 2 payments
|
2020: $22,447
| Allergan | Vraylar | $19,013 | 24 payments
|
| Sunovion Pharmaceuticals | Latuda | $3,398 | 9 payments
|
| Avanir Pharmaceuticals | Nuedexta | $20 | 1 payment
|
| Janssen Pharmaceuticals | Invega Sustenna | $16 | 1 payment
|
2019: $46,391
| Allergan | Vraylar | $42,716 | 71 payments
|
| Teva Pharmaceuticals USA | Austedo | $2,903 | 7 payments
|
| Sunovion Pharmaceuticals | Latuda | $350 | 1 payment
|
| Allergan | Vraylar | $200 | 1 payment
|
| Vanda Pharmaceuticals | Fanapt | $116 | 6 payments
|
| Otsuka America Pharmaceutical | Rexulti | $106 | 1 payment
|
Professional record
- NPI
- 1790820942
- Licence
- CA A80278California A80278: Current · expires 2028-01-31
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 401 Quarry Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-21
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.